Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Overview

  • Study type

    Interventional
  • Study phase

    II
  • Study IDs

  • Describes the nature of a clinical study. Types include:

    • Observational study — observes people and measures outcomes without affecting results.
    • Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
    • Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
  • During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

  • Site IRB
    • Rochester, Minnesota: 17-008059
    NCT ID: NCT02867592
    Sponsor Protocol Number: ADVL1622

About this study

This phase II trial studies how well cabozantinib-s-malate works in treating younger patients with sarcomas, Wilms tumor, or other rare tumors that have come back, do not respond to therapy, or are newly diagnosed. Cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for tumor growth and tumor blood vessel growth.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

See eligibility criteria

Inclusion Criteria:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  • Age: Patients must be ≥ 2 and ≤ 30 years of age at the time of study entry for all strata except upper age limit of ≤ 18 years of age for MTC, RCC and HCC.
  • Body Surface Area (BSA): Patients must have a body surface area ≥ 0.35 m2.
  • Diagnosis: Patients must have recurrent or refractory disease, or newly diagnosed disease with no known curative therapy or therapy proven to prolong survival with an acceptable quality of life. Patients must have had histologic verification of one of the malignancies listed below at original diagnosis or at relapse:
    • Ewing sarcoma;
    • Rhabdomyosarcoma (RMS);
    • Non-rhabdomyosarcoma soft tissue sarcomas (STS) including microphthalmia transcription factor associated STS (alveolar soft part sarcoma (ASPS) and clear cell sarcoma (CCS));
    • Osteosarcoma;
    • Wilms tumor.
    • Rare tumors
      • Medullary thyroid carcinoma (MTC);
      • Renal cell carcinoma (RCC);
      • Hepatocellular carcinoma (HCC);
      • Hepatoblastoma;
      • Adrenocortical carcinoma;
      • Pediatric solid tumors (including CNS tumors) with known molecular alterations in the targets of XL184 (i.e., MET amplification, overexpression, activating mutation, MET translocation, MET exon skipping mutations, activating RET mutations, RET rearrangement, overexpression or activation of AXL). Documentation of the alteration from a CLIA certified laboratory will be required;
      • Note: Documentation of any known tumor molecular alterations and RET mutation status for patients with MTC (germline) must be uploaded via the RAVE system.

Disease Status

  • Patients must have radiographically measurable disease.
  • Measurable disease is defined as the presence of at least one lesion on MRI or CT scan that can be accurately measured with the longest diameter a minimum of 10 mm in at least one dimension (CT scan slice thickness no greater than 5 mm).
    • Note: The following do NOT qualify as measurable disease:
      • malignant fluid collections (e.g., ascites, pleural effusions);
      • bone marrow infiltration;
      • lesions only detected by nuclear medicine studies (e.g., bone, gallium or PET scans);
      • elevated tumor markers in plasma or CSF;
      • previously radiated lesions that have not demonstrated clear progression post radiation;
      • leptomeningeal lesions that do not meet the measurement parameters noted above.

Performance Level

  • Patients must have a Lansky or Karnofsky performance status score of ≥ 50, corresponding to ECOG categories 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score  (see https://members.childrensoncologygroup.org/prot/reference_materials.asp).

Prior Therapy

  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
  • Myelosuppressive chemotherapy:
    • Solid Tumors:
      • Patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea).
  • Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.
  • Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or ANC counts): ≥ 7 days after the last dose of agent. See DVL homepage for commercial and investigational agent classifications. For agents not listed, the duration of this interval must be discussed with the study chair and the study-assigned Research Coordinator prior to enrollment.
  • Antibodies: ≥ 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to Grade ≤ 1.
  • Radiotherapy: ≥ 2 weeks must have elapsed since local palliative XRT (small port); ≥ 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; ≥ 3 months must have elapsed if prior craniospinal XRT was received, if ≥ 50% of the pelvis was irradiated, or if TBI was received; ≥ 6 weeks must have elapsed if other substantial bone marrow irradiation was given.  Subjects should not have any clinically relevant ongoing complications from prior radiation therapy (i.e., radiation esophagitis or other inflammation of the viscera).
  • Stem Cell Transplant or Rescue without TBI: No evidence of active graft vs. host disease and ≥ 2 months must have elapsed since transplant.
  • Study specific limitations on prior therapy: Not previously received XL184 or another MET/HGF inhibitor (tivantinib or crizotinib). There are no limits on number of prior therapeutic regimens. Patients who have been treated with prior VEGF pathway, or RET inhibitors (except XL184) may be eligible.

Organ Function Requirements

  • Adequate Bone Marrow Function Defined As:
  • For patients with solid tumors without bone marrow involvement:
    • Peripheral absolute neutrophil count (ANC) ≥1000/μL;
    • Platelet count ≥100,000/μL (transfusion independent, defined as not receiving platelet transfusions within a 7 day period prior to enrollment);
    • Hemoglobin ≥8.0 g/dL (may receive RBC transfusions).
  • For patients with solid tumors and known bone marrow metastatic disease:
    • Peripheral absolute neutrophil count (ANC) ≥750/μL;
    • Platelet count ≥50,000/μL;
    • Hemoglobin ≥8.0 g/dL.
  • Transfusions are permitted to meet both the platelet and hemoglobin criteria. Patients must not be known to be refractory to red blood cell or platelet transfusions.
  • Adequate Renal Function Defined As:
    • Creatinine clearance or radioisotope GFR ≥70 mL/min/1.73 m2 or a serum creatinine based on age/gender as follows:
    • Age | Maximum Serum Creatinine (mg/dL) | Male | Female
    • 2 to < 6 years | Male 0.8 | Female 0.8
    • 6 to < 10 years | Male 1.0 | Female 1.0
    • 10 to < 13 years | Male 1.2 | Female 1.2
    • 13 to < 16 years | Male 1.5 | Female 1.4
    • ≥16 years | Male 1.7 | Female 1.4
      • The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR (Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC.
    • Urine protein: ≤ 30 mg/dl in urinalysis or ≤ 1+ on dipstick, unless quantitative protein is < 1000 mg in a 24 h urine sample.
  • Adequate Liver Function Defined As:
    • Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age ;
    • SGPT (ALT) ≤ 135 U/L (3x ULN) (for the purpose of this study, the ULN for SGPT is 45 U/L);
    • Serum albumin ≥ 2.8 g/dL.
  • Adequate Cardiac Function Defined As:
    • No history of congenital prolonged QTc syndrome, NYHA Class III or IV congestive heart failure (CHF);
    • No clinically significant cardiac arrhythmias, stroke or myocardial infarction within 6 months prior to enrollment;
    • QTc ≤ 480 msec.
      • Note: Patients with Grade 1 prolonged QTc (450- 480 msec) at the time of study enrollment should have correctable causes of prolonged QTc addressed if possible (i.e., electrolytes, medications).
  • Central Nervous System Function Defined As:
    • Patients with a known seizure disorder who are receiving non-enzyme inducing anticonvulsants and have well-controlled seizures may be enrolled. See Appendix VII for a list of recommended non-enzyme inducing anticonvulsants;
    • CNS toxicity ≤ Grade 2 with the exception of decreased tendon reflex (DTR). Any grade of DTR is eligible.
  • Adequate Blood Pressure Control defined as:
    • A blood pressure (BP) ≤ the 95th percentile for age, height, and gender for pediatric patients < 18 years old (Appendix V) and ≤ 140/90 mmHg for patients ≥ 18 years old. BP should be measured as described in Section 5.5, and patients should not be receiving medication for treatment of hypertension (except patients with Wilms tumor and RCC who may be eligible if on stable doses of no more than one anti-hypertensive medication with a baseline BP ≤ ULN for pediatric patients and ≤ 140/90 for adult patients). Please note that 3 serial blood pressures should be obtained and averaged to determine baseline BP.
  • Adequate Coagulation Defined as:
    • INR ≤ 1.5.
  • Adequate Pancreatic Function Defined as:
    • Serum amylase ≤ 1.5 x ULN;
    • Serum lipase ≤ 1.5 x ULN.

Exclusion Criteria:

  • Pregnant or breastfeeding
    • Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-menarchal. Males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control- during protocol therapy and for at least 4 months after the last dose of XL184. Abstinence is an acceptable method of birth control.
  • Concomitant Medications
    • Growth factor(s): Growth factors that support platelet or white cell number or function must not have been administered within the 7 days prior to enrollment (14 days if pegfilgrastim).
    • Corticosteroids: Patients requiring corticosteroids who have not been on a stable or decreasing dose of corticosteroid for the 7 days prior to enrollment are not eligible. If used to modify immune adverse events related to prior therapy, ≥ 14 days must have elapsed since last dose of corticosteroid.
    • Previous treatment with XL184 (cabozantinib) or another MET/HGF inhibitor (tivantinib, crizotinib).
    • Investigational Drugs: Patients who are currently receiving another investigational drug are not eligible.
    • Anti-cancer Agents: Patients who are currently receiving other anti-cancer agents are not eligible.
    • Anti-GVHD or agents to prevent organ rejection post-transplant.
    • Patients who are receiving cyclosporine, tacrolimus or other agents to prevent either graft-versus-host disease post bone marrow transplant or organ rejection post-transplant are not eligible for this trial
    • CYP3A4 active agents: Patients must not be receiving any of the following potent CYP3A4 inducers or inhibitors: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John’s wort. A list of other known CYP3A4 inducers and inhibitors that should be discontinued prior to initiation of protocol therapy and should be avoided during study therapy if reasonable alternatives exist is included in Appendix II.
    • Concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin, and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel) are prohibited.
      • Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimen.
    • Enzyme-inducing Anticonvulsants: Patients must not have received enzyme–inducing anticonvulsants within 14 days prior to enrollment.
    • QTc Agents: Patients who are receiving drugs that prolong QTc are not eligible.
  • Patients who are unable to swallow intact tablets are not eligible.
  • Patients who have an uncontrolled infection are not eligible.
  • Patients who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study are not eligible.
  • Patients with active bleeding are not eligible. Specifically, no clinically significant GI bleeding, GI perforation, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment. Patients with evidence of an acute intracranial or intratumoral hemorrhage on CT or MRI are not eligible (patients with evidence of resolving hemorrhage will be eligible). In patients with CNS tumors, an MRI with ECHO gradient sequences would be required to exclude presence of petechial hemorrhages.
  • Patients who have had or are planning to have the following invasive procedures are not eligible:
    • Major surgical procedure, laparoscopic procedure, or open biopsy within 28 days prior to enrollment.
    • Central line placement or subcutaneous port placement is not considered major surgery but must be placed at least 3 days prior to enrollment for external lines (e.g., Hickman or Broviac catheter, peripherally inserted central catheter (PICC)) and at least 7 days prior to enrollment for a subcutaneous port.
    • Core biopsy within 7 days prior to enrollment.
    • Fine needle aspirate within 7 days prior to enrollment.
    • Surgical or other wounds must be adequately healed prior to enrollment
      • NOTE: For purposes of this study, bone marrow aspirate and biopsy are not considered surgical procedures and therefore are permitted within 14 days prior to start of protocol therapy.
  • Patients who have had significant traumatic injury within 28 days prior to enrollment are not eligible.
  • Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of the study drug are not eligible.

Regulatory

  • All patients and/or their parents or legal guardians must sign a written informed consent.
  • All institutional, FDA, and NCI requirements for human studies must be met.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Carola A Arndt, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

Additional contact information

Cancer-related trials contact form

Phone: 855-776-0015 (toll-free)

International patient clinical studies questions